Institutional shares held 16 Million
1.73M calls
1.71M puts
Total value of holdings $197M
$21.3M calls
$21.2M puts
Market Cap $335M
24,346,200 Shares Out.
Institutional ownership 65.64%
# of Institutions 133


Latest Institutional Activity in CAPR

Top Purchases

Q4 2024
Farallon Capital Management LLC Shares Held: 2.25M ($30.9M)
Q4 2024
State Street Corp Shares Held: 2.21M ($30.3M)
Q4 2024
Vanguard Group Inc Shares Held: 2.28M ($31.3M)
Q4 2024
Woodline Partners LP Shares Held: 630K ($8.66M)
Q4 2024
Morgan Stanley Shares Held: 632K ($8.68M)

Top Sells

Q4 2024
Superstring Capital Management LP Shares Held: 55.2K ($759K)
Q4 2024
Advisor Group Holdings, Inc. Shares Held: 6.3K ($86.6K)
Q4 2024
Pfm Health Sciences, LP Shares Held: 54.4K ($747K)
Q4 2024
Jpmorgan Chase & CO Shares Held: 16.7K ($229K)
Q4 2024
Eam Investors, LLC Shares Held: 38.3K ($526K)

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.


Insider Transactions at CAPR

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
2.96M Shares
From 9 Insiders
Exercise of conversion of derivative security 163K shares
Grant, award, or other acquisition 3.34K shares
Open market or private purchase 2.8M shares
Sell / Disposition
15K Shares
From 2 Insiders
Other acquisition or disposition 12.5K shares
Payment of exercise price or tax liability 2.54K shares

Track Institutional and Insider Activities on CAPR

Follow CAPRICOR THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CAPR shares.

Notify only if

Insider Trading

Get notified when an Capricor Therapeutics, Inc. insider buys or sells CAPR shares.

Notify only if

News

Receive news related to CAPRICOR THERAPEUTICS, INC.

Track Activities on CAPR